Home Cart Sign in  
Chemical Structure| 2448414-54-6 Chemical Structure| 2448414-54-6

Structure of JMV 2959 HCl
CAS No.: 2448414-54-6

Chemical Structure| 2448414-54-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JMV 2959 is an antagonist of the GHS-R1a growth hormone secretagogue receptor, with an IC50 of 32 nM, commonly used in research on endocrine and metabolic diseases.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JMV 2959 HCl

CAS No. :2448414-54-6
Formula : C30H33ClN6O2
M.W : 545.08
SMILES Code : O=C(N[C@@H](C1=NN=C(CCC2=CC=CC=C2)N1CC3=CC=C(OC)C=C3)CC4=CNC5=C4C=CC=C5)CN.[H]Cl
MDL No. :MFCD31715444

Safety of JMV 2959 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of JMV 2959 HCl

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice D1R-mediated kindling model Intraperitoneal injection 5 mg/kg Administered 30 min prior to each SKF81297 injection, observed for 45 min Evaluate the effects of JMV-2959 on seizures in the D1R-mediated kindling model, showing no differences in seizure severity and number. Int J Mol Sci. 2019 May 20;20(10):2480
Rats Conditioned place preference (CPP), intravenous self-administration (IVSA), and behavioral stimulation models Intraperitoneal injection 1 or 3 mg/kg Single or repeated administration, lasting for 8 days (CPP) or 3 days (IVSA) JMV2959 significantly and dose-dependently reduced THC-induced conditioned place preference and behavioral stimulation, as well as WIN55,212-2 intravenous self-administration and relapse-like behavior Int J Mol Sci. 2021 Feb 27;22(5):2397
Rats Conditioned place preference (CPP) and intravenous self-administration (IVSA) models Intraperitoneal injection 1, 3, and 6 mg/kg Single or multiple administrations, experiments conducted 20 minutes after each administration JMV2959 significantly reduced methamphetamine-induced conditioned place preference (CPP) expression and decreased methamphetamine intravenous self-administration (IVSA) and relapse-like behavior. Int J Mol Sci. 2018 Sep 26;19(10):2925
Rats Opioid-induced changes in dopamine, endocannabinoids, and GABA concentrations in the nucleus accumbens shell model Intraperitoneal, VTA injection, or NAC perfusion 3 mg/kg (i.p.) or 2 µg/10 µg (VTA) or 8 mM/40 mM (NAC perfusion) Single administration, monitored for 3 hours JMV2959 pre-treatment significantly reversed fentanyl-induced anandamide increases in the NACSh, resulting in a significant AEA decrease and intensified fentanyl-induced decreases in accumbens 2-AG levels, while also reducing fentanyl-evoked GABA efflux and behavioral stimulation. Int J Mol Sci. 2017 Nov 22;18(11):2486
Rat Wistar rats Intraperitoneal injection 3 mg/kg Single administration To investigate the effects of JMV2959 on WIN55,212-2-induced behavioral stimulation and dopamine release in the nucleus accumbens. Results showed that JMV2959 significantly reduced WIN55,212-2-induced behavioral stimulation and dopamine release in the nucleus accumbens. Int J Mol Sci. 2020 Dec 28;22(1):210
Mice and rats Alcohol dependence models Intraperitoneal injection 9 mg/kg (mice) and 1, 2, 4 mg/kg (rats) Once daily for 5 days (mice) and twice weekly for 7 days (rats) JMV2959 reduced ethanol intake but did not affect ethanol preference. In rats, JMV2959 reduced operant self-administration of both ethanol and sucrose. Neuropharmacology. 2015 Oct;97:182-93

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.83mL

0.37mL

0.18mL

9.17mL

1.83mL

0.92mL

18.35mL

3.67mL

1.83mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories